corporate presentation march 2019...corporate presentation march 2019. disclaimer ... a trusted...
TRANSCRIPT
CSE: VGW
OTC: VGWCF
CORPORATE PRESENTATION
MARCH 2019
DISCLAIMER
This Presentation contains forward-looking statements and forward-looking information. Often, but not always, forward-looking statements can be identified by the use of words or
phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and
unknown words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words
and risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements and information. Examples of such statements include: (A) the financial forecast of the
Company; (B) the intention to grow the business and operations of the Company; (C) anticipated timing for the availability of the Company’s products to market and expected sale
prices; (D) expected growth in the number of users of medical and recreational marijuana anticipated; and (E) the expansion of the Company’s business into other revenue streams.
Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this Presentation.
Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to: the ability of the Company to obtain
necessary financing; the ability to complete a going public transaction; the ability to satisfy the requirements of a stock exchange; the economy generally; consumer interest in the
products of the Company; competition; and anticipated and unanticipated costs. These forward-looking statements should not be relied upon as representing the Company’s views
as of any date subsequent to the date of this Presentation. Although the Company has attempted to identify important factors that could cause actual actions, events or results to
differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended.
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements and information contained in this Presentation are
expressly qualified in their entirety by this cautionary statement. The forward-looking statements and information included in this Presentation are made as of the date of this
Presentation and the Company assumes no obligation to update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by
applicable securities legislation.
NOTICE TO RECIPIENT
This investment is suitable only for sophisticated investors for whom an investment does not constitute a complete investment program, who do not require immediate liquidity for
their investment and who fully understand and are willing to assume the risks involved. An investment may be considered to involve a substantial degree of risk, and an investor
could lose all or a substantial amount of his or her investment. This document is not an offer to sell (or solicitation of an offer to buy) any interest in the Company. These materials
may not be used or relied upon for any purpose other than as specifically contemplated by a written agreement. The materials may not be circulated outside of the recipient’s
organization, publicly referred to, or disclosed, in whole or in part, without express written permission. This presentation does not purport to be all inclusive or contain all the
information that a prospective investor may require to fully evaluate an investment in the contemplated transaction. Prospective investors should conduct their own thorough
investigation and due diligence before making an investment.
2
CSE:VGW, OTC:VGWCF
3
Our mission is to become the
world’s most trusted partner for
best-in-class cannabis
extraction, testing, formulations
and product development.
CSE:VGW, OTC:VGWCF
Largest extraction
company in Canada.
Most diverse
extraction capabilities.
In-house testing
laboratory.
High
margins.
High cashflow
visibility.
First mover
advantage.
Providing customers with the widest variety of
extraction techniques which allows them to
produce the largest range of end products.
Customized
product development.Valens formulation and testing expertise allows for
the production of a wide array of tinctures, capsules,
concentrates, vapes, topicals, beverages and edibles.
Proprietary technology
and processes.
At 240,000kg of capacity and growing, Valens
is equipped to service Canadian demand as well
as the global markets with efficiency at scale.
Setting global standards, Valens Labs was the first
ISO 17025 accredited lab for cannabis analyses and
is endorsed by $100B+ Thermo Fisher Scientific as
the Centre of Excellence in Plant Based Science.
Operating in the highest margin sub-sector of
the cannabis industry with low variability in
costs.
Substantial, reoccurring agreements with leading
producers, including Canopy, Tilray and Organigram
providing a clear revenue and cashflow path.
Incorporated in 2012, Valens was granted the first
Dealer’s License to process cannabis. Our R&D and
testing process allows us to quickly identify market
trends and adapt to a changing landscape.
4
Decades of experience have resulted in a best in class
proprietary extraction process that is optimized to
produce consistently high quality products.
CSE:VGW, OTC:VGWCF
INVESTMENT HIGHLIGHTS
2016
“The future of cannabis in Canada is coming, and we are at the forefront.”
– Tyler Robson, CEO
FUTURE*2018
5
FLOWER BASED PRODUCTSOIL BASED PRODUCTS
Source: Cowen Equity Research Report
*Valens forward-looking prediction in the short-term based on market research
29%
71%
47%53%
25%
75%
CSE:VGW, OTC:VGWCF
US MARKET SHARE ROAD MAP
OUR BELIEFSTHE MARKET IS RAPIDLY MOVING TO OIL BASED PRODUCTS
6
1
2
3
4
EXTRACTION
TESTING
FORMULATION
PRODUCT DEVELOPMENT
CSE:VGW, OTC:VGWCF
WHAT WE DOVALENS KEY FOCUS AREAS
7
1
OIL EXTRACTION
OIL WINTERIZATION
DRIED
CANNABISOIL REFINEMENT
(DISTILLATE/ISOLATE)CBD
THC
CBGCBN
WAXES
LIPIDS
FATS
CSE:VGW, OTC:VGWCF
EXTRACTIONWHAT IS IT?
Valens is the only company providing a wider variety of extraction methods
allowing us to create more end products and ultimately meeting a larger number of customer needs.
EXTRACTION
8
Capsules
Tinctures
Vapes
Topicals
Beverages
Edibles
Others
Concentrates
Vapes
Shatter/Wax
Full Spectrum
Rosin
Hash
Live Resin
Add back for
experience, flavour
and smell
1
Capsules
Tinctures
Vapes
Edibles
Super/Sub
Critical CO2 Ethanol Hydrocarbon Solvent-less Terpene
CSE:VGW, OTC:VGWCF
EXTRACTIONWHAT IS OUR COMPETITIVE ADVANTAGE?
RESIN REFINED OIL
Processing from
flower to crude oil
Processing from crude oil
to various refined stages
Formulation and product
development of oil for market
Fee for service Fee for service Fee for service
or
Revenue share
9
INCREASING MARGINS
WHITE LABEL
1
CSE:VGW, OTC:VGWCF
EXTRACTIONHOW WE GENERATE HIGH MARGINS
EXTRACTION
• Trusted by industry-leading producers
• 2 to 4 year renewable contracts with minimum
annual quantities
• Recognized for our expertise and ability to deliver
high quality extracts
EXTRACTION PARTNERSEXTRACTING FOR $45B WORTH OF MARKET CAP
A key element of [our] success is
partnerships with companies like Valens
who can offer the capacity, quality and
expertise to help ensure we deliver on our
ongoing commitment to meeting the
increasing demand of the global medical
and adult recreational cannabis markets.
-Greg Engel, CEO of Organigram
10
STRATEGIC PARTNERSGLOBAL INITIATIVES
1
…AND MORE
CSE:VGW, OTC:VGWCF
EXTRACTIONA TRUSTED INDUSTRY PARTNER
METALS PESTICIDES TERPENES RESIDUAL SOLVENTS MICROBIALS CANNABINOID PROFILES
11
First ISO 17025 accredited lab - the global gold
standard for testing laboratories.
Utilizing the latest state of the art instrumentation,
Valens can perform analyses that typically take a
minimum of 5 days in as little as 24 hours.
Working with Thermo Fisher Scientific to publish fully
validated, standardized, and turnkey solutions for
the cannabis industry to increase the confidence in
laboratory results world-wide.
Additional revenue source through third-party lab
testing (required by Health Canada for all producers)
TESTINGVALENS LABS: SETTING STANDARDS DOMESTICALLY
AND GLOBALLY FOR CANNABIS TESTING
Named a “Center of Excellence in
Plant Based Science” by Thermo
Fisher Scientific.
Annual Revenue: $24B USD
Market Cap: $104B USD
Global Employees: 70,000
2
Consumer products are built on trust. This starts and ends with reliability and consistency.
CSE:VGW, OTC:VGWCF
12
3
As the cannabis market matures, custom
formulations will drive consumer
preference more and more.
Tasteless, colorless and odorless
Full spectrum preservation or flower
emulating characteristics
Customized flavor introductions
500+ BIOACTIVE COMPOUNDS
ARE PRESENT IN CANNABIS
140+
CANNABINOIDS100+
TERPENES
20+ FLAVONOIDSPHENOLIC
AMIDES
STEROLS
CSE:VGW, OTC:VGWCF
FORMULATIONSDIFFERENT COMBINATIONS OF MOLECULES CREATE DIFFERENT CONSUMER EXPERIENCES
Alpha Pinene3%
PINEAPPLE
EXPRESS*
13
3
100+ TERPENE FORMULATIONS
Cannabinoids bind to the body’s
receptors to produce different
effects, which are further
influenced by terpenes and the
full suite of secondary compounds.
Valens has the capabilities and
expertise to create and customize
terpene formulations responsible
for consumer experience.
*Example of the terpene make-up of the
cannabis strain, Pineapple Express
CSE:VGW, OTC:VGWCF
FORMULATIONSTHE IMPORTANCE OF SECONDARY COMPOUNDS
• Shelf stable for over 360 days (not proven anywhere else)
• Zero cannabis taste, color or odor
• Provides effective, consistent dosing
• Lower dosage sufficient due to increase in bioavailability when consumed
• Faster onset making it the safer and more trusted option. Observed in 5-15 minutes versus normal 30 minutes – 2 hours.
• Faster offset making it feel exactly like an alcoholic beverage. Observed in 45 minutes – 2 hours versus normal 4 – 8 hours.
• Proprietary formula, exclusive Canadian rights
14
3
CSE:VGW, OTC:VGWCF
WATER SOLUBILITY
ONSET
OFFSET
SMELL/TASTE
CONSISTENCY
SHELF STABILITY
CURRENT PROBLEMS VALENS’ SOLUTION
FORMULATIONSSORSE EMULSION TECHNOLOGY
CANNABIS AS AN
INGREDIENT
VAPE
BEVERAGES/EDIBLES
TOPICALS/CAPSULES
TINCTURES
154
V A L E N S W H I T E L A B E L P R O D U C T O F F E R I N G S
CSE:VGW, OTC:VGWCF
PRODUCT DEVELOPMENTTHE FUTURE OF CANNABIS CONSUMPTION
GEOGRAPHIC EXPANSION
EXPORT GLOBALLY
LAUNCH BEVERAGES
& EDIBLES
LAUNCH VAPE LINE
16
KELOWNA EXPANSION
EU GMP CERTIFICATION
ORGANIC CERTIFICATION
VARIOUS MULTI-YEAR
EXTRACTION AND PRODUCT
DEVELOPMENT CONTRACTS
ACHIEVEMENTS IN 2018
EXTRACTION CAPACITY EXPANSION
8 PUBLIC MULTI-YEAR EXTRACTION AGREEMENTS
PARTNERSHIP WITH THERMO FISHER SCIENTIFIC
ISO 17025 VALENS LABS ACCREDITATION
STANDARD PROCESSING, CULTIVATION AND
ANALYTICAL TESTING LICENSES
GLOBAL PARTNERSHIPS FOR SUPPLY
GLOBAL PARTNERSHIPS FOR DISTRIBUTION
SORSE EXCLUSIVE TECH & BEVERAGE RIGHTS
OTC LISTING
KEY MANAGEMENT, ADVISORY AND BOARD
ADDITIONS
RAISED $41 MILLION IN CAPITAL
CSE:VGW, OTC:VGWCF
2018 ACHIEVEMENTS
CORPORATEWHAT WE’VE ACCOMPLISHED AND WHERE WE’RE GOING
FOCUS FOR 2019
C A N A D A
CURRENT GLOBAL PARTNERSHIPS
INCLUDE ETICANN (COLOMBIA)
AND MEDIGROWTH (AUSTRALIA)
TARGETTING EUROPEAN
DISTRIBUTION AND EXPANSION
G L O B A L
M A R K E T
17
A U S T R A L IA
C O L O M B IA
* E IG H T C A P IT A L R E S E A R C H 2 0 18
33 COUNTRIES WITH
ACTIVE MEDICAL
LEGISLATION*
CSE:VGW, OTC:VGWCF
CORPORATEGLOBAL MEDICAL MARKET ALONE ESTIMATED AT $180B ANNUALLY IN 10-20 YEARS*
Broker Date Rating Target (C$) Commentary
AltaCorp Capital Inc. Mar 14, 2019 Outperform $7.00
"Within the cannabis sector and amongst all companies we have seen, we forecast that Valens will generate one of the most attractive EBITDA margin profiles. In addition, the Company’s business model requires relatively low capital investment in comparison to the business models of most vertically integrated cannabis producers, allowing them to generate meaningful free cash flows as early as F2020. Based on our forecasted financial performance, Valens offers a very attractive opportunity to invest in what we believe is an undervalued and uniquely positioned business."
Haywood Securities Inc. Feb 7, 2019 Buy $5.25
"We believe that Valens’ proprietary extraction process and development of oil derivative based products, both white-label and its own branded products should result in strong revenue growth and solid EBITDA margins. Throughout 2019 we expect the Company to scale revenues through its existing agreements while also announcing further agreements to leverage its processing capacity."
Mackie Research Capital Corp.
Feb 27, 2019 Buy $6.00
Over the past couple of months, Valens has signed multi-year cannabis extraction agreements with Tilray, Organigram, Canopy Growth, Sundial Growers, Harvest One and GTEC Holdings. Following the contract announcements with Tilray and Organigram, we have made adjustments to our revenueand earnings forecasts through F2020 and on the back of these new forecasts we are increasing our target price to $6.00 from $4.50.
ANALYSTS OUTLOOK
CAPITALIZATION TABLE
18
CSE:VGW, OTC:VGWCF
CORPORATEFINANCIALS & OUTLOOK
(In CAD$MM, unless otherwise noted)Share Price: As of 21st of March 2019 $3.14
Basic Shares O/S 108.6 Fully Diluted Shares O/S 123.9
Equity Value $389.0 Cash and Cash Equivalents $60.8 Investments in Other Companies $4.7 ITM Securities $30.9 Debt $0.0
Enterprise Value $292.6
Financials (Based on Analyst Estimates) CY2019 CY2020 CY2021Revenue $48.7 $116.5 $171.2 EBITDA $23.6 $61.5 $84.4
Trading Multiples CY2019 CY2020 CY2021EV/Revenue 6.0x 2.5x 1.7xEV/EBITDA 12.4x 4.8x 3.5x
Source: Company Filings, S&P Capital IQ, AltaCorp Capital Inc.
As of March 21st, 2019; Shares outstanding based on most recent quarterly financials and adjusted for share issuance
transactions and other significant publicly disclosed transactions; presented as Treasury Stock Method
NO. OF ANNOUNCED TOLL
PROCESSING AGREEMENTS
WITH LICENSED PRODUCERS
NO. OF ANNOUNCED TOLL
AGREEMENTS IN TOP 10*
CURRENT ANNUAL
EXTRACTION CAPACITY
TYPES OF EXTRACTION
ISO 17025 ACCREDITED
TESTING LAB
EU GMP CERTIFICATION
ORGANIC CERTIFICATION
MARKET CAP (CAD$) Per Comp Table (p.25)
8
4
240,000KG
5
Y
PENDING
PENDING
389M
1
1
30,000KG
2
N
N
N
365M
5
1
150,000KG
1
N
PENDING
N
456M
2
1
56,000KG
1
N
N
N
323M
*Companies ranked per market cap
Sourced from company presentations and news releases
19
CSE:VGW, OTC:VGWCF
COMPETITIVE LANDSCAPE
Largest extraction
company in Canada.
Most diverse
extraction capabilities.
In-house testing
laboratory.
High
margins.
High cashflow
visibility.
First mover
advantage.
Providing customers with the widest variety of
extraction techniques which allows them to
produce the largest range of end products.
Customized
product development.Valens formulation and testing expertise allows for
the production of a wide array of tinctures, capsules,
concentrates, vapes, topicals, beverages and edibles.
Proprietary technology
and processes.
At 240,000kg of capacity, Valens is equipped to
service Canadian demand as well as the global
markets with efficiency at scale.
Setting global standards, Valens labs was the first
ISO 17025 accredited lab for cannabis analyses and
is endorsed by $100B+ Thermo Fisher Scientific as
the Centre of Excellence in Plant Based Science.
Operating in the highest margin sub-sector of
the cannabis industry with low variability in
costs.
Substantial, reoccurring agreements with leading
producers, including Canopy, Tilray and Organigram
providing a clear revenue and cashflow path.
Incorporated in 2012, Valens was granted the first
Dealer’s License to process cannabis. Our R&D and
testing process allows us to quickly identify market
trends and adapt to a changing landscape.
20
Decades of experience have resulted in a best in class
proprietary extraction process that is optimized to
produce consistently high quality products.
CSE:VGW, OTC:VGWCF
INVESTMENT HIGHLIGHTS
21
W W W . V A L E N S G R O W O R K S . C O M
L O C A T I O N
2 3 0 C A R I O N R D .
K E L O W N A , B R I T I S H C O L U M B I A
C O N T A C T U S
S C O T T @ V A L E N S G R O W O R K S . C O M
( 7 0 5 ) 8 8 8 - 2 7 5 6
22
CSE:VGW, OTC:VGWCF
Share Market Equity Total Enterprise Revenue(1) EBITDA(1) EV/Revenue EV/EBITDA
Ticker Price Cap(1) Value Debt Value CY2019E CY2020E CY2019E CY2020E CY2019E CY2020E CY2019E CY2020E
(C$) (C$ MM) (C$MM) (C$MM) (C$MM) (C$MM) (C$MM) (C$MM) (C$MM) (x) (x) (x) (x)Canadian Large Cap CompaniesCanopy Growth Corporation TSX:WEED $61.50 $29,920 $29,920 $61 $19,242 $686 $1,224 $92 $296 28.0x 15.7x 209.9x 65.0xAurora Cannabis Inc. TSX:ACB $12.78 $14,448 $14,448 $829 $14,039 $586 $1,129 $36 $302 23.9x 12.4x 390.7x 46.4xTilray, Inc. NasdaqGS:TLRY $94.09 $9,575 $9,575 $642 $9,353 $282 $594 ($47) $58 33.2x 15.7x >500.0x >100.0xCronos Group Inc. TSX:CRON $27.47 $11,961 $11,961 $71 $8,104 $110 $259 $38 $90 74.0x 31.3x 215.6x 89.9xAphria Inc. TSX:APHA $13.39 $3,450 $3,450 $55 $3,247 $570 $973 $87 $228 5.7x 3.3x 37.3x 14.2xHEXO Corp. TSX:HEXO $9.04 $2,671 $2,671 $51 $2,141 $185 $453 $24 $122 11.6x 4.7x 88.1x 17.6xOrganiGram Holdings Inc. TSXV:OGI $9.39 $1,542 $1,542 $13 $1,407 $157 $256 $60 $99 8.9x 5.5x 23.4x 14.3xCannTrust Holdings Inc. TSX:TRST $13.31 $1,581 $1,581 $10 $1,393 $181 $281 $50 $93 7.7x 5.0x 27.8x 14.9xThe Green Organic Dutchman TSX:TGOD $5.02 $1,619 $1,619 $0 $1,158 $93 $510 ($8) $102 12.4x 2.3x NMF 11.4xThe Supreme Cannabis Company, Inc. TSX:FIRE $2.25 $841 $841 $105 $750 $96 $163 $26 $47 7.8x 4.6x 28.8x 15.9xZenabis Global Inc. TSXV:ZENA $3.29 $709 $709 $75 $665 $167 $337 $13 $80 4.0x 2.0x 51.6x 8.3xThe Flowr Corporation TSXV:FLWR $6.00 $597 $597 $0 $539 $24 $94 ($0) $29 22.7x 5.7x NMF 18.6xAleafia Health Inc. TSX:ALEF $2.18 $622 $622 $20 $539 $142 $300 $25 $84 3.8x 1.8x 21.6x 6.4xEmerald Health Therapeutics, Inc. TSXV:EMH $4.45 $725 $725 $25 $643 $4 N/A ($19) ($16) >50.0x N/A NMF NMFWestleaf Inc. TSXV:WL $2.91 $434 $434 $4 $410 N/A N/A N/A N/A N/A N/A N/A N/AVIVO Cannabis Inc. TSXV:VIVO $1.12 $338 $338 $45 $277 $75 $196 $11 $54 3.7x 1.4x 24.2x 5.1xWeedMD Inc. TSXV:WMD $2.08 $256 $256 $0 $201 $59 $140 $16 $42 3.4x 1.4x 12.3x 4.8x48North Cannabis Corp. TSXV:NRTH $1.50 $265 $265 $2 $201 N/A N/A N/A N/A N/A N/A N/A N/AWayland Group Corp. CNSX:WAYL $0.91 $176 $176 $26 $129 $124 $176 $16 $43 1.0x 0.7x 8.3x 3.0xDelta 9 Cannabis Inc. TSXV:NINE $1.75 $150 $150 $0 $111 $83 $161 $21 $29 1.3x 0.7x 5.2x 3.8xInvictus MD Strategies Corp. TSXV:GENE $0.84 $106 $106 $1 $95 $69 $84 $23 $22 1.4x 1.1x 4.2x 4.4xJames E. Wagner Cultivation Corporation TSXV:JWCA $1.04 $99 $99 $6 $89 $35 $59 $3 $16 2.6x 1.5x 35.0x 5.7xHarvest One Cannabis Inc. TSXV:HVT $1.08 $249 $249 $2 $192 $57 $126 $9 $36 3.4x 1.5x 21.7x 5.4xBeleave Inc. CNSX:BE $0.09 $39 $39 $6 $43 $36 $12 ($14) $7 1.2x 3.7x NMF 6.6xIndiva Limited TSXV:NDVA $0.54 $46 $46 $5 $34 $20 $67 ($3) $19 1.7x 0.5x NMF 1.8xMean 12.0x 5.6x 70.9x 17.3xCanadian Extraction CompaniesMediPharm Labs Corp. TSXV:LABS $3.39 $456 $456 $2 $404 $97 $184 $21 $55 4.2x 2.2x 19.1x 7.3xNeptune Wellness Solutions Inc. TSX:NEPT $4.28 $356 $356 $4 $330 $53 $119 $10 $28 6.3x 2.8x 32.1x 11.6xValens Groworks Corp. CNSX:VGW $3.14 $389 $389 $0 $292 $49 $117 $24 $61 6.0x 2.5x 12.4x 4.8xRadient Technologies Inc. TSXV:RTI $1.07 $323 $323 $7 $273 N/A N/A N/A N/A N/A N/A N/A N/AMean 5.5x 2.5x 21.2x 7.9x
Mean - All 11.2x 5.2x 63.5x 16.1x
Source: Company Filings, S&P Capital IQ, AltaCorp Capital
As of March 21st, 2019; shares outstanding based on most recent quarterly financials and adjusted for share issuance transactions and other significant publicly disclosedtransactions; presented as fully diluted with all in-the-money securities added to the equity value and cash proceeds added to diluted cash balance; N/D = Not Disclosed (1) Basedon Analyst consensus estimates
APPENDIX: COMP TABLE
23
Scott Young
Head of Investor Relations
Mr. Young has spent the past 15 years working in the
capital market sectors of Canada, the United States and
Europe. Beyond this, he has extensive business
development experience in Hong Kong, North and South
America.
Dawn Visintainer, M.Sc.
Head of Quality Assurance
Mrs. Visintainer has extensive experience in QA/QC
laboratories as well as being a research scientist in the
natural health products industry. She also has experience
setting up and managing ISO 17025 accredited labs in both
the natural health space and the cannabis space.
Everett Knight
Executive Vice President, Strategy & Investments
Mr. Knight holds almost a decade of experience in Portfolio
Management and Investments. At Matco Financial, he
launched the first ever institutional long only cannabis fund in
Canada and managed a small cap fund, ranked #1 in its
category.
Chris Buysen, MPAcc CPA, CA
Chief Financial officer
Mr. Buysen has over 15 years of diverse financial
experience working as a senior financial executive with
many public and private organizations in a wide range of
industries.
Anderson Smith
Head of Regulatory Affairs
Anderson was been involved in the scientific analytical
testing space specializing in the analysis of natural health
products for over 15 years. He brings this expertise coupled
with his extensive knowledge of regulatory regime to
Valens.
Chantel Popoff
Chief Operating Officer
Ms. Popoff has over a decade of experience in managing
21+ Western Canadian retail pharmacy chains, including
Shoppers Drug Mart. She also has over 6 years of senior
managerial experience in the Canadian natural health
food industry.
Quinn Shiskin
Head of Production
Mr. Shiskin brings his knowledge of extraction from 12 years
of experience as a dual ticketed Red Seal tradesman.
Throughout this time he studied the cannabis industry with
top alchemists in the US creating a deep understanding of
the plant from seed to oil, specializing in all methods of
extraction.
Tyler Robson, B.Sc.
Director, Chief Executive Officer and Co-founder.
Mr. Robson has over a decade of cannabis R&D, plant
innovation and life sciences experience. He previously held
the position of COO of Valens Agritech Ltd. prior to
becoming CEO in 2017.
CSE:VGW, OTC:VGWCF
APPENDIX: KEY MANAGEMENT
Brett Channer
Advisor, CEO of Mass Minority, Past CEO of Saatchi +
Saatchi
Mr. Channer has over 25 years of marketing industry
experience. He was responsible for leading Saatchi Canada
to “Most Improved Agency in Canada” as well as one of the
Top 10 creative agencies in Canada and becoming one of
the top performing agencies for growth in the Saatchi
Network. Tyler Robson, B.Sc.
Director, CEO and Co-founder
Mr. Robson has over a decade of cannabis R&D, plant
innovation and life sciences experience. He previously held
the position of COO of Valens Agritech Ltd. “Top 100
Leaders in Health Care” by IFAH.
Ashley McGrath
Director, President & Owner of Glencoe Developments Inc.
Mr. McGrath has been involved in real estate development for
14 years, overseeing all aspects of the development business
and oversees the management of multiple development
companies in the commercial, residential and agricultural
space.
Chris Irwin
Director, Partner at Irwin Lowy LLP.
Mr. Irwin advises a number of public companies on a
variety of matters including continuous disclosure and
regulatory matters, reverse takeover transactions, initial
public offerings and take over bids.
Nitin Kaushal, CPA, CA
Director, Managing Director, Corporate Finance at PwC
Canada. Mr. Kaushal has over 30 years of finance and
investment expertise including having held a number of
senior roles with Canadian investment banks, private
equity and venture capital industry.
Chris Buysen, MPAcc CPA, CA
Director, CFO
Mr. Buysen has over 15 years of diverse financial
experience working as a senior financial executive with
many public and private organizations in a wide range
industries.
Phil Donne
Advisor, Past President/CEO of Campbell Company of
Canada, Past CEO of Kellogg Canada
Mr. Donne brings over 30 years of international brand
management, re-structures and bold brand and
communication initiatives including the re-launch of Vector
cereal which still remains the largest new cereal product in
20 years.
24
CSE:VGW, OTC:VGWCF
APPENDIX: BOARD & ADVISORS